BackgroundBreast cancer is one of the most common cancers and the leading cause of death from cancer among women worldwide. The genetic predisposition to breast cancer may be associated with a mutation in particular genes such as gene BRCA1/2. Patients who carry a germline pathogenic mutation in BRCA1/2 genes have a significantly increased risk of developing breast cancer and might benefit from targeted therapy. However, genetic testing is time consuming and costly. This study aims to predict the risk of gBRCA mutation by using the whole-slide pathology features of breast cancer H&E stains and the patients’ gBRCA mutation status.MethodsIn this study, we trained a deep convolutional neural network (CNN) of ResNet on whole-slide images (W...
Pathologic assessment of tissue sections is an important part of breast cancer diagnosis, with early...
The treatment of patients with ERBB2 (HER2)-positive breast cancer with anti-ERBB2 therapy is based ...
Background BRCA1/2 deleterious variants account for most of the hereditary breast and ovarian can...
Abstract Homologous Recombination DNA-repair deficiency (HRD) is a well-recognized marker of platinu...
Due to the highest mortality rate in the globe, cancer still poses a severe threat to individuals to...
Introduction: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Introduction: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Accurate detection of HER2 expression through immunohistochemistry (IHC) is of great clinical signif...
INTRODUCTION: Mutations in BRCA1 and BRCA2 confer high risks of breast cancer and ovarian cancer. Th...
In the last four years, advances in Deep Learning technology have enabled the inference of selected ...
Introduction: Mutations in BRCA1 and BRCA2 confer high risks of breast cancer and ovarian cancer. Th...
IntroductionThe distribution of histopathological features of invasive breast tumors in BRCA1 or BRC...
INTRODUCTION: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Advanced diagnostics are enabling cancer treatments to become increasingly tailored to the individua...
Abstract Introduction The distribution of histopathol...
Pathologic assessment of tissue sections is an important part of breast cancer diagnosis, with early...
The treatment of patients with ERBB2 (HER2)-positive breast cancer with anti-ERBB2 therapy is based ...
Background BRCA1/2 deleterious variants account for most of the hereditary breast and ovarian can...
Abstract Homologous Recombination DNA-repair deficiency (HRD) is a well-recognized marker of platinu...
Due to the highest mortality rate in the globe, cancer still poses a severe threat to individuals to...
Introduction: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Introduction: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Accurate detection of HER2 expression through immunohistochemistry (IHC) is of great clinical signif...
INTRODUCTION: Mutations in BRCA1 and BRCA2 confer high risks of breast cancer and ovarian cancer. Th...
In the last four years, advances in Deep Learning technology have enabled the inference of selected ...
Introduction: Mutations in BRCA1 and BRCA2 confer high risks of breast cancer and ovarian cancer. Th...
IntroductionThe distribution of histopathological features of invasive breast tumors in BRCA1 or BRC...
INTRODUCTION: The distribution of histopathological features of invasive breast tumors in BRCA1 or B...
Advanced diagnostics are enabling cancer treatments to become increasingly tailored to the individua...
Abstract Introduction The distribution of histopathol...
Pathologic assessment of tissue sections is an important part of breast cancer diagnosis, with early...
The treatment of patients with ERBB2 (HER2)-positive breast cancer with anti-ERBB2 therapy is based ...
Background BRCA1/2 deleterious variants account for most of the hereditary breast and ovarian can...